申请人:Merck & Co., Inc.
公开号:US06326372B1
公开(公告)日:2001-12-04
Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
本文披露了内酰胺和环脲衍生物及其药用盐。还描述了这些化合物的合成以及它们作为α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物通常在其能够放松α1a受体亚型丰富的平滑肌组织的同时,不会引起低血压。这种组织包括尿道内膜周围的组织。因此,这些化合物的一个用途是为患有良性前列腺增生的男性提供急性缓解,从而减少尿液流动的阻碍。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合,从而可以实现对良性前列腺增生影响的急性和慢性缓解。